Product Description: LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
Applications: Cancer-Kinase/protease
Formula: C28H27F4N7O3S
Citations: Hepatology. 2022 Sep 21./Hepatology. 2023 May 1;77(5):1580-1592./Immunity. 2021 Sep 14;54(9):2042-2056.e8./Pharmacol Res. 2021 Oct 4;105871./Theranostics. 2022 Jan 1;12(3):1204-1219./Harvard Medical School LINCS LIBRARY
References: [1]Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50(5):867-75./[2]Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75(1):40-50./[3]Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12(8):e0182891.
CAS Number: 1082949-68-5
Molecular Weight: 617.62
Compound Purity: 98.58
Research Area: Cancer
Solubility: DMSO : 10.25 mg/mL (ultrasonic;warming)
Target: Ribosomal S6 Kinase (RSK)
Deutsch
English
